Vaxcyte Long Term Debt Total from 2010 to 2025

PCVX Stock

USD 70.70 2.14 3.12%

Vaxcyte Long Term Debt Total yearly trend continues to be fairly stable with very little volatility. Long Term Debt Total will likely drop to about 384.8 K in 2025. During the period from 2010 to 2025, Vaxcyte Long Term Debt Total regression line of annual values had r-squared of 0.75 and arithmetic mean of 2,297,922. View All Fundamentals

Long Term Debt Total

First Reported

2010-12-31

Previous Quarter

405 K

Current Value

384.8 K

Quarterly Volatility

1.7 M

Credit Downgrade

Yuan Drop

Covid

Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 115.5 M, Interest Expense of 0.0 or Selling General Administrative of 97.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.

Check out the analysis of Vaxcyte Correlation against competitors.

For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Long Term Debt Total Growth Pattern

Below is the plot of the Long Term Debt Total of Vaxcyte over the last few years. It is Vaxcyte's Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.

Long Term Debt Total

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Long Term Debt Total

Timeline

Vaxcyte Long Term Debt Total Regression Statistics

	Arithmetic Mean	2,297,922
	Geometric Mean	1,458,423
	Coefficient Of Variation	73.88
	Mean Deviation	1,630,713
	Median	3,760,000
	Standard Deviation	1,697,819
	Sample Variance	2.9T
	Range	3.4M
	R-Value	(0.87)
	Mean Square Error	767.7B
	R-Squared	0.75
	Significance	0.000014
	Slope	(309,128)
	Total Sum of Squares	43.2T

Vaxcyte Long Term Debt Total History

	2025	384.8 K
	2024	405 K
	2019	450 K
	2018	3.6 M

Other Fundumenentals of Vaxcyte

Short Long Term Debt Total

Vaxcyte Long Term Debt Total component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Net Receivables	Deferred Long Term Liab
Total Assets		1.0	0.89	-0.97	0.93	-0.62	-0.62	0.77	0.63	0.98	0.92	0.79	-0.55	-0.5	1.0	0.8	0.98	0.46	0.94	0.73
Total Stockholder Equity	1.0		0.89	-0.97	0.93	-0.6	-0.6	0.77	0.6	0.98	0.92	0.79	-0.53	-0.5	1.0	0.8	0.98	0.46	0.94	0.73
Net Tangible Assets	0.89	0.89		-0.94	0.81	-0.76	-0.76	0.92	0.58	0.96	0.98	0.9	-0.72	-0.78	0.9	0.94	0.96	0.74	0.9	0.88
Retained Earnings	-0.97	-0.97	-0.94		-0.89	0.71	0.71	-0.84	-0.7	-0.99	-0.97	-0.87	0.65	0.56	-0.97	-0.89	-0.98	-0.55	-0.98	-0.83
Accounts Payable	0.93	0.93	0.81	-0.89		-0.67	-0.67	0.79	0.58	0.9	0.88	0.66	-0.6	-0.49	0.93	0.76	0.9	0.54	0.83	0.59
Long Term Debt	-0.62	-0.6	-0.76	0.71	-0.67		1.0	-0.88	-0.68	-0.71	-0.8	-0.77	1.0	0.65	-0.63	-0.81	-0.69	-0.83	-0.65	-0.76
Long Term Debt Total	-0.62	-0.6	-0.76	0.71	-0.67	1.0		-0.88	-0.68	-0.71	-0.8	-0.77	1.0	0.65	-0.63	-0.81	-0.69	-0.83	-0.65	-0.76
Capital Surpluse	0.77	0.77	0.92	-0.84	0.79	-0.88	-0.88		0.51	0.85	0.95	0.9	-0.85	-0.72	0.78	0.93	0.84	0.91	0.79	0.88
Total Liab	0.63	0.6	0.58	-0.7	0.58	-0.68	-0.68	0.51		0.65	0.62	0.54	-0.65	-0.31	0.62	0.64	0.63	0.28	0.69	0.56
Total Current Assets	0.98	0.98	0.96	-0.99	0.9	-0.71	-0.71	0.85	0.65		0.97	0.85	-0.65	-0.65	0.98	0.88	1.0	0.59	0.95	0.81
Common Stock	0.92	0.92	0.98	-0.97	0.88	-0.8	-0.8	0.95	0.62	0.97		0.91	-0.76	-0.69	0.93	0.94	0.97	0.74	0.93	0.88
Property Plant Equipment	0.79	0.79	0.9	-0.87	0.66	-0.77	-0.77	0.9	0.54	0.85	0.91		-0.74	-0.6	0.8	0.88	0.85	0.75	0.85	0.98
Current Deferred Revenue	-0.55	-0.53	-0.72	0.65	-0.6	1.0	1.0	-0.85	-0.65	-0.65	-0.76	-0.74		0.65	-0.56	-0.79	-0.63	-0.83	-0.6	-0.74
Net Debt	-0.5	-0.5	-0.78	0.56	-0.49	0.65	0.65	-0.72	-0.31	-0.65	-0.69	-0.6	0.65		-0.51	-0.72	-0.65	-0.78	-0.45	-0.63
Net Invested Capital	1.0	1.0	0.9	-0.97	0.93	-0.63	-0.63	0.78	0.62	0.98	0.93	0.8	-0.56	-0.51		0.81	0.98	0.48	0.94	0.74
Capital Stock	0.8	0.8	0.94	-0.89	0.76	-0.81	-0.81	0.93	0.64	0.88	0.94	0.88	-0.79	-0.72	0.81		0.87	0.78	0.84	0.92
Net Working Capital	0.98	0.98	0.96	-0.98	0.9	-0.69	-0.69	0.84	0.63	1.0	0.97	0.85	-0.63	-0.65	0.98	0.87		0.58	0.94	0.81
Short Term Debt	0.46	0.46	0.74	-0.55	0.54	-0.83	-0.83	0.91	0.28	0.59	0.74	0.75	-0.83	-0.78	0.48	0.78	0.58		0.48	0.76
Net Receivables	0.94	0.94	0.9	-0.98	0.83	-0.65	-0.65	0.79	0.69	0.95	0.93	0.85	-0.6	-0.45	0.94	0.84	0.94	0.48		0.81
Deferred Long Term Liab	0.73	0.73	0.88	-0.83	0.59	-0.76	-0.76	0.88	0.56	0.81	0.88	0.98	-0.74	-0.63	0.74	0.92	0.81	0.76	0.81

Click cells to compare fundamentals

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Long Term Debt Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Long Term Debt Total	405 K	384.8 K
Short and Long Term Debt Total	71.1 M	74.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vaxcyte Long Term Debt Total from 2010 to 2025

Latest Vaxcyte's Long Term Debt Total Growth Pattern

Vaxcyte Long Term Debt Total Regression Statistics

Vaxcyte Long Term Debt Total History

Other Fundumenentals of Vaxcyte

Vaxcyte Long Term Debt Total component correlations

About Vaxcyte Financial Statements

Also Currently Popular

Additional Tools for Vaxcyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY